Back

Renal safety and clinical effectiveness of peri-hospitalization SGLT2 inhibitor initiation in acute heart failure: a systematic review and meta-analysis

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in acute heart failure - pharmacotherapy (1) Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mrs Joyce Gu

Erie (United States of America)

4 More presentations in this session

Presentation thumbnail
Impact of early in-hospital SGLT2 inhibitor use on mortality in acute heart failure: a real-world cohort study
Doctor N. Benameur (Tangier, MA)
Abstract Slides
Presentation thumbnail
Factors associated with early initiation of SGLT2 inhibitors in hospitalized heart failure patients
Doctor D. Darabantiu (Arad, RO)
Abstract Slides
Presentation thumbnail
Ambulatory levosimendan administration in advanced heart failure: results from a single-center registry
Doctor J. Van Loock (Hasselt, BE)
Abstract Slides
Presentation thumbnail
Vericiguat in Italian clinical practice: insights from the OpTIMa-HF registry and comparison with the VICTORIA trial
Doctor F. Marzano (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
ePosters in acute heart failure - pharmacotherapy (1)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice
thumbnail
Congress Session
Devices in acute heart failure
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources